News Highlights:

- The U.S. FDA approved Neurocrine Bioscience's **Ongentys** for treating "**off episodes**" of **Parkinson's disease**. It is approved for use in combination with levodopa and carbidopa to extend time before a patient's symptoms return. Because of the COVID-19 pandemic, Neurocrine will delay the launch of the drug until later this year. <u>https://www.fiercepharma.com/pharma/neurocrine-scores-fda-nod-for-parkinson-s-drug-ongentys-but-won-t-</u> <u>launch-amid-pandemic</u>

- The FDA sent warning letters this week to 10 companies that make **vaping-related products aimed at young people**. The products include sweatshirts and backpacks designed to hide vaping cartridges and vaping devices that look like toys, candy, or smart watches.

https://www.msn.com/en-us/news/us/fda-takes-aim-at-vaping-products-meant-to-look-like-candy-toys/ar-BB13hinw

https://www.fda.gov/news-events/press-announcements/fda-warns-manufacturers-and-retailers-remove-certain-ecigarette-products-targeted-youth-market

- The U.S. FDA approved Eli Lilly's anxiety and depression drug **Cymbalta (duloxetine)** for treating **fibromyalgia in teenagers**. Fibromyalgia is characterized by widespread muscle pain and fatigue. Cymbalta's only other approved **pediatric use** is for treating **generalized anxiety disorder**. The drug has a boxed warning for increased risk of suicidal thinking and behavior in children, teens, and young adults.

Cymbalta is approved for these additional indications in adults: **major depression, diabetic neuropathy, and chronic muscular-skeletal pain**. A revised label was posted this week. The approval was based on a small clinical trial involving 184 pediatric patients, with 149 finishing the trial; while the study showed no improvement for primary (pain) outcomes, improvements were demonstrated for drug vs. placebo for secondary outcomes. Updated drug label:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021427s052lbl.pdf

Patient reviews (adults) of Cymbalta for fibromyalgia:

https://www.askapatient.com/viewrating.asp?drug=21427&name=CYMBALTA&Reason=fibromyalgia

- The U.S. FDA authorized **emergency use** of Gilead's investigational drug **remdesivir** for treating severe cases (where oxygen therapy is needed) of COVID-19. The drug is authorized to be administered by **intravenous infusion in hospitals only**. The approval was based on a government-sponsored clinical trial involving about 1,000 patients. There have been some questions raised as to why the primary clinical trial outcome measurement was changed while the trial was ongoing-- from how many patients were kept alive using the drug to how long it took surviving patients to recover. Remdesivir was found to reduce an average hospital stay from 15 days to 11 days.

https://www.washingtonpost.com/business/2020/05/01/government-researchers-changed-metric-measurecoronavirus-drug-remdesivir-during-clinical-trial/

FDA press release on remdesivir: <u>https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment</u>

- Results from a 10-hospital study of **remdesivir** between February 6 and March 12, 2020 involving 237 patients with COVID-19 were published in *The Lancet* this week. Researchers reported that the drug was "**not**

associated with statistically significant clinical benefits." The study, conducted in Hubei China, was terminated on March 29 because of lack of new patient enrollment. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext? mod=article_inline#seccestitle70

- While global demand for novel coronavirus tests soar, concerns are mounting that companies are **shifting production away from tests for HIV, malaria, and tuberculosis**. The coronavirus tests are more lucrative for manufacturers; a COVID-19 test can fetch \$10 compared with about 19 cents per test for a rapid malaria test. https://www.theguardian.com/world/2020/may/01/demand-for-coronavirus-tests-raises-concerns-over-hiv-and-malaria

COVID-19 and Nursing Homes

- In response to the devastating impact of COVID-19 on residents and staff of long-term care facilities, the **Center for Medicare Services (CMS)** announced a new independent commission that will conduct a comprehensive **assessment of the nursing home response** to the 2019 Novel Coronavirus pandemic. <u>https://www.cms.gov/newsroom/press-releases/cms-announces-independent-commission-address-safety-and-quality-nursing-homes</u>

- California reported that 40% of the state's COVID-19 deaths were residents or staff at long-term care facilities. The *Los Angeles Times* reports that the percentage is likely higher. Similarly, New Jersey reported that while 1% of their population is in nursing homes, 40% of COVID-19 deaths are from nursing homes. In **Europe**, the share of COVID-19 deaths from long-term care facilities is also in this range, according to the World Health Organization.

California: <u>https://www.latimes.com/california/story/2020-04-29/california-coronavirus-related-deaths-nursing-homes</u>

New Jersey:

https://www.northjersey.com/story/news/coronavirus/2020/04/17/coronavirus-nj-nursing-home-deaths-account-40-percent-njs-fatalities/5155332002/

This chart with data from the California Department of Health, while from April 17, gives infection rates for more than 1,000 nursing homes in California. It shows a significant number of staff testing positive for COVID-19, which is leading to infections of residents of nursing homes: <u>https://flo.uri.sh/visualisation/2014317/embed</u>

The reported deaths may not include those that occurred after a resident was transferred to a hospital, a private home or other location, according to the *Los Angeles Times*.

- In Maryland, Governor Larry Hogan announced mandatory COVID-19 testing of all residents and staff at all nursing homes. Some other states and cities are doing the same, including West Virginia, San Francisco, Los Angeles, and Oklahoma. About 19% of infections and 48% of fatalities in Maryland are linked to nursing homes or long-term care facilities.

https://www.foxnews.com/us/maryland-coronavirus-universal-testing-nursing-home-residents-staff

- Confirmed cases of COVID-19 globally as of 3 May, 2020, 5 pm: **3,485,948**, with 1,149,197 of those cases reported in the United States. Fatalities number **246,475** with 67,447 of those in the U.S. Johns Hopkins University Coronavirus dashboard:

https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

The newsletter will be in brief format for the next few weeks as we work on web site enhancements. You may always check out the real-time news feeds on general, mental health, seniors health, FDA news, and more on the web site:

https://www.askapatient.com/news/pharmnews.asp

AskaPatient Weekly Healthcare Newsletter 5-03-2020

Trouble viewing this email? View it as a web page.

Subscribe and visit us at https://www.askapatient.com

Check out the up-to-date health news feed on our web site: <u>Pharm News</u>

Unsubscribe from the weekly newsletter.

Please contact us with suggestions, comments, or questions: <u>admin@askapatient.com</u> We welcome your feedback.



Copyright © *|CURRENT_YEAR|* AskaPatient ®